FDA Clears CraniUS Patient-Specific Cranial Implant for US Market

A Patient-Specific Cranial Plate Clears the FDA

The US Food and Drug Administration has granted 510(k) clearance to the CraniUS Plate, a patient-specific cranial implant manufactured by Baltimore-based CraniUS Therapeutics. The clearance, issued July 29, 2026 under submission K261058, marks the company's first product cleared for commercial use in the United States.

Each CraniUS Plate is individually designed and 3D-printed to match the specific anatomy of the patient receiving it. That matters because no two cranial defects are identical. Whether the damage comes from trauma, a tumour resection, or a decompressive craniectomy, surgeons currently rebuild with plates that approximate the missing bone. A custom implant closes that gap more precisely than an off-the-shelf option.

The device is regulated as a Class II preformed alterable cranioplasty plate and was reviewed by the FDA's Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices. It is cleared only for repair of cranial defects, not for investigational uses that the company is still developing.

A Platform With Ambitions Beyond the First Product

CraniUS Therapeutics was founded in 2021 and closed a $20 million Series B round earlier this year. The CraniUS Plate, internally designated NeuroPASS 1, is the foundation of a broader platform the company calls NeuroPASS. The long-term plan includes implants that provide durable brain access, integrated sensing, and a fully implantable drug-delivery system capable of bypassing the blood-brain barrier.

Those capabilities remain investigational and have not received FDA authorization. Each program will require its own regulatory pathway. The architecture is designed so that future features can be added to the same cleared base implant as each capability matures.

Michael Maglin, CEO of CraniUS Therapeutics, described the clearance as an inflection point that moves the company from development to a product surgeons can actually use. Dr. Chad Gordon, Founder and Chief Medical Officer, noted that cranial reconstruction has been treated as a purely structural problem for decades, overlooking the space beneath the plate as a site for therapeutic intervention.

For patients, the immediate benefit is a better-fitting implant at a time when their skull anatomy has already been disrupted. For the broader industry, the clearance adds another data point showing that patient-specific, 3D-printed implants can move through the FDA's 510(k) pathway.